Background: Cost-effectiveness is one of the major limitations for tumor molecular profiling along with a small fraction of patients who can benefit from precision oncology approach. Our experience of providing an affordable molecular profiling (AMP) proves that focused biomarker panels and specific selection of patients for testing are the possible ways to overcome those obstacles. Methods: NGS assays were performed with AmpliSeq targeted panels. Data were analyzed with a proprietary pipeline. Apart from routine searching for nonsynonymous substitutions, NGS data were processed with custom-built algorithms for identifying amplifications, splice-affecting variants and evaluation of tumor mutational load. Within our concept of AMP in some cases, the following techniques were used to identify the additional biomarkers: MSI-assay, FISH (gene fusions), PD-L1 and others. Results: First 79 patients were analyzed. The most common cancer types were: breast cancer -17, colorectal cancer -12, lung cancer -8 and rare tumor types. In 14 cases (15.1%), patients were denied molecular profiling due to there were conventional treatment options or extremely low chances to detect actionable alterations. The average total costs of the study were -50704 rubles or less than 700 Euros per patient. In 22% of cases, there were found biomarkers of 2B, 3A/B, and 4 levels of evidence (according to OncoKB.org) since biomarkers 1 and 2A levels have almost always been studied in patients. Our proprietary algorithm detected actionable amplifications in NGS data from 2 patients. Pretreated patient with stage IV cervical cancer was indicated to afatinib treatment due to amplified EGFR. The treatment resulted in complete response and stable remission during next 6 months. The second case was metastatic colorectal cancer with amplification of FLT3 gene who demonstrated a partial clinical response to sorafenib. In both cases, all standard treatment options were exhausted. Conclusions: Reasonable selection of biomarker panels helps to reduce costs and ensure the better clinical utility of routine tumor molecular profiling. Legal entity responsible for the study: OncoAtlas, LLC. Background: Triple-negative breast cancer (TNBC) subtype is associated with an adverse outcome among BC patients. Since Overall Survival (OS) and recurrence prediction are significant to define suitable treatment strategies, an identification of prognostic markers for Disease-Free Survival (DFS) and OS is relevant. Here we aimed to estimate the effects of previously identified predictors of DNA-damaging therapy POLR2L, RAD50, SLC34A2, SMARCA5 and WDHD1 on OS and DFS in TNBC. Methods: Clinicopathological data of 1098 BC patients (TCGA Breast Invasive Carcinoma) and information of expression and copy number alterations (CNA) of
Background: Triple-negative breast cancer (TNBC) subtype is associated with an adverse outcome among BC patients. Since Overall Survival (OS) and recurrence prediction are significant to define suitable treatment strategies, an identification of prognostic markers for Disease-Free Survival (DFS) and OS is relevant. Here we aimed to estimate the effects of previously identified predictors of DNA-damaging therapy POLR2L, RAD50, SLC34A2, SMARCA5 and WDHD1 on OS and DFS in TNBC. Methods: Clinicopathological data of 1098 BC patients (TCGA Breast Invasive Carcinoma) and information of expression and copy number alterations (CNA) of DFS and features, such as tumor stage, patient's age at diagnosis, expression and CNAs of genes of interest were evaluated using Cox Proportion Hazard models and Log-rank test. Statistical analysis was performed utilizing the computing environment R. Results: Among studied covariates, high mRNA expression of POLR2L (HR ¼ 1.7; 95% CI: 1.16-2.48; p-value ¼ 0.006) and RAD50 (HR ¼ 1.9; 95% CI: 1.02-3.64; p-value ¼ 0.043) genes and the progressive stage of disease (HR ¼ 4.0; 95% CI: 2. 08-7.68; pvalue ¼3.15x10 -5 ) were associated with worse OS of TNBC patients. Also high mRNA expression of POLR2L (HR ¼ 1.9; 95% CI: 1.16-3.00; p-value ¼ 0.01) gene and progressive stage of disease (HR ¼ 3.379; 95% CI: 1.601-7.132; p-value ¼ 0.001) were associated with increased risk of cancer relapse. All possible combinations of the examined genes and characteristics were tested to select a most powerful prognostic model. For OS ) and DFS ) the best multivariate Cox regression model included a combination of mRNA expression of POLR2L and RAD50 genes and tumor stage. Conclusions: Our findings display that the mRNA expression of POLR2L and RAD50 genes both separately and in combination with a stage of disease influence on OS and DFS of TNBC patients. Thus, POLR2L and RAD50 could be considered as new potential prognostic markers of TNBC. Background: From decades' immortal cells have been used as a model system to study the mechanism of cancer, drug resistance and explore the potential efficacy of the anticancer drugs. However, the numerous study has been suggested that studying the immortal cancer has a backdrop to represent the drug resistance and heterogeneity of the tumor in the patients. So, Primary tumor cultures currently begin to constitute the golden standard to study the lacking things, which has to apply to study the mechanism of resistance and personalized therapy including in breast tumor. Methods: Initially, 10 breast tumors with different subtypes were obtained from patients, with their informed consent. They were freshly taken biopsy samples. The patient biopsies underwent an enzymatic digestion with (3 mg /ml collagenase and 5unit/ml dispase). After enzymatic digestion cells were grown in normal complete media with different growth factors and ROCK inhibitor. All cell lines were maintained until their passage (p15-p20). The cells were characterized with different antibodies by flow cytometry, different gene expression and protein expression were assessed by PCR and western blot. Results: Here we found that, after characterization of the 10 samples, the most subpopulations have the breast cancer stem cells properties (CD44þ/CD24low) as well as cancer-associated fibroblast (CAFs) characteristics with the positive expression of CD 140a. In the gene level, we found that the mesenchymal marker (fibronectin) and an oncofetal gene i.e. SALL4 are overexpressed in almost all cells except in Luminal B her2þ subtype, as compared to MCF 10a (a non-tumorigenic epithelial cell line). Further, we are impending to correlate the expression of metastatic and tumorigenic targets in those individual patients with cell proliferation, invasion, migration and drug efficacy. Conclusions: The present study provided that the primary cell culture can be a better way to study the mechanism behind metastasis and drug resistance. It also contributes to the knowledge behind the cell heterogeneity and increases the drug's efficacy. Primary tumor cell lines have the potential to improve the effectiveness of conventional clinical approaches to treat cancer of individual patients. Legal entity responsible for the study: 1) INCLIVA Biomedical Research Institute 2) CIBERONC. Funding: CIBERONC. Disclosure: All authors have declared no conflicts of interest.
48P Oncogenes and cancer-associated thrombosis: Is there a rationale for using molecular findings to assess thromboembolic risk in cancer patients?
L. Provenzano, M. Platania Istituto Nazionale Tumori, Milan, Italy
Background: Cancer-associated thrombosis (CAT) is one of the most threatening complications of cancer. Many questions are as yet unsolved in this field, from pathogenesis to clinical management. One of the most interesting issues is the role of oncogenes and oncosuppressors as link between carcinogenesis and CAT. There is much evidence on in vitro capacity of some oncogenes to enhance the clotting system, but less clinical evidence of association between cancer mutational status and risk of thromboembolic events. The aim of this study was to explore the relationship between mutational status of genes commonly analysed and risk of CAT. Through a selective neoadjuvant therapy, either chemotherapy or endocrine therapy using histopathologic markers and 70-gene assay (Mammaprint. Agendia inc.), we hypothesize that we could increase the breast conservation rate in lumnal A type breast cancer.
Trial design: This study is a non-randomized, phase II, prospective study. The main inclusion criteria is women with stage I-IIIA, ER-positive, HER-2 negative breast cancer that tumor size is measurable. Breast conserving surgery (BCS) is not feasible considering the turmor size, location, and patient's breast size. Two surgeons in each institution will judge the feasibility of BCS. Main exclusion criteria is diffuse malignant microcalcifiation or multicentrica breast cancer. The conversion rate from BCS-ineligible to BCSeligible with NCT was 35.8% in luminal A breast cancer in our previous study. We assumed that with the study regimen, the rate will be increased to 50.8% (15% increase). Given these estimates, under 10% type I error rate and 70% power, 220 patients in total will be enrolled from nine tertiary hospitals in Korea. All the patients initially will be tested with Mammaprint assay. When the Mammprint result is high risk, the patients will receive NCT. When the Mammprint result is low risk, the patients will receive neoadjuvant endocrine therapy. Postmenopausal women receive letrozole 2.5mg per day for 16 weeks. Premenopausal women receive leuprorelin every 4 weeks with letrozole for 16 weeks. The primary endpoint is conversion rate from BCSineligible to BCS-eligible of more than 50%. The secondary endpoint is actual breast conservation rate. pathologic complete response. clinical response rate, and diseasefree survival.
Legal entity responsible for the study: Korean Breast Cancer Study Group (KBCSG). Funding: Agendia Takeda Kwandong Pharmaceutical Co Ltd. Korea Shin Poong Pharm, Co. Ltd. Disclosure: The author has declared no conflicts of interest.
